$5 Billion Oceania #Cannabis Consumer Market; Fueled by Canadian Imports, #Australia's …

SYDNEY – October 25, 2018 (Investorideas.com Newswire) New Frontier Data, today’s authority in data, analytics and business intelligence on the global cannabis industry, announces the publication of The Oceania Cannabis Report, 2018 Industry Outlook to be released at CannaTech Sydney on Monday, October 29, 2018. New Frontier Data, the first company to rigorously study and assess the size and potential opportunity of legal cannabis in the Oceanic region, estimates total market demand, both legal and illicit, to be worth close to $5 Billion USD. The Oceanic region, comprising Australasia, Melanesia, Micronesia and Polynesia, spans an area of 3.3 million square miles and could contribute almost 3 million consumers to the regional cannabis market.

“New Frontier Data research shows the potential in Oceania to be quite large within this culturally diverse region, with Australia and New Zealand having the most progressive cannabis attitudes and highest rates of use. Cannabis acceptance and legalization by these two nations will significantly influence changes in cannabis adoption and regulation throughout the region,” said New Frontier Data Founder & CEO Giadha Aguirre de Carcer. “As these countries consider expanded lists of qualifying conditions for medical cannabis, levels of patient participation are expected to steadily climb, creating a legal medical market comparable in many ways to Canada’s national medical cannabis market.”

Australia plans to become a global cannabis supplier once domestic production gets underway and to date has already issued 18 cultivation licenses, 10 research licenses and 13 manufacturing licenses, signaling significant regional market aspirations.

“Attitudes toward cannabis are evolving quickly in the region,” added Aguirre de Carcer. “For example, the U.S. Territory of the Northern Mariana Islands recently became the first territory in the region to fully legalize adult use.”

Among the report’s key findings:

The existing cannabis market across Oceania is worth an estimated $5.0 billion (U.S. dollars)

Australia – which accounts for more than 60% of the region’s population – commands the lion’s share of market demand in the region, with approximately 12% of the total adult population in the country consuming cannabis at least once per year

Australia’s medical cannabis patient population could reach 330,000 or 1.2% of the population by 2025

New Zealand’s medical cannabis patient population could reach 70,000 or 1.36% of the population by 2025

Visit NewFrontierData.com/Oceania to obtain a copy of the full report, which contains many more findings on the countries and territories in Oceania that have advanced medical and/or adult-use legalization.

About New Frontier Data:

New Frontier Data is an independent, technology-driven analytics company specializing in the cannabis industry. It offers vetted data, actionable business intelligence and risk management solutions for investors, operators, researchers and policymakers. New Frontier Data’s reports and data have been cited in over 69 countries around the world to inform industry leaders. Founded in 2014, New Frontier Data is headquartered in Washington, D.C. with additional offices in Denver, CO, London, UK, Bogota, Colombia, and Hong Kong.

New Frontier Data does not take a position on the merits of cannabis legalization. Rather, its mission and mandate are to inform cannabis-related policy and business decisions through rigorous, issue-neutral and comprehensive analysis of the legal cannabis industry worldwide. For more information about New Frontier Data please visit: http://www.NewFrontierData.com.

Marijuana / Hemp Stocks info for investors

This news is published on the Investorideas.com Newswire – a global digital news source for investors and business leaders

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Additional info regarding BC Residents and global Investors: Effective September 15 2008 – all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Source: https://www.investorideas.com/news/2018/cannabis/10252Australia-MedicalMarket.asp

Previous Dressing Room Anxieties
Next Analysis | With pot legalized, job openings surge in Canada's cannabis industry